Study #2022-0717
A phase 1b dose finding study assessing safety and activity of 177LuLu-DOTA-TATE in newly diagnosed glioblastoma in combination with radiotherapy with or without Temozolomide and in recurrent glioblastoma as single agent
MD Anderson Study Status
Enrolling
Treatment Agent
[177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE
Description
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma
Study phase:
Phase I
Physician name:
Nazanin Majd
Department:
Neuro-Oncology
For general questions about clinical trials:
1-844-274-8956
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.